Cyclo Therapeutics Inc (CYTH)
0.74
+0.01
(+1.37%)
USD |
NASDAQ |
Nov 05, 16:00
0.74
0.00 (0.00%)
After-Hours: 20:00
Cyclo Therapeutics Research and Development Expense (Annual): 14.18M for Dec. 31, 2023
Research and Development Expense (Annual) Chart
Historical Research and Development Expense (Annual) Data
| Date | Value |
|---|---|
| December 31, 2023 | 14.18M |
| December 31, 2022 | 9.000M |
| December 31, 2021 | 9.154M |
| December 31, 2020 | 6.096M |
| December 31, 2019 | 4.869M |
| December 31, 2018 | 2.711M |
| Date | Value |
|---|---|
| December 31, 2017 | 2.293M |
| December 31, 2016 | 1.865M |
| December 31, 2015 | 0.6585M |
| December 31, 2014 | 0.0941M |
| December 31, 2013 | 0.00 |
R&D Expense Definition
R&D expense is a line item from many companies' income statements.
Research and Development Expense (Annual) Range, Past 5 Years
4.869M
Minimum
2019
14.18M
Maximum
2023
8.660M
Average
9.000M
Median
2022
Research and Development Expense (Annual) Benchmarks
| Stryker Corp | 1.388B |
| Biogen Inc | 2.462B |
| Pfizer Inc | 10.68B |
| Pacira BioSciences Inc | 76.26M |
| Moderna Inc | 4.845B |